Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial

Objectives: In this study, we aimed to evaluate the non-inferiority of a quadrivalent influenza vaccine (QIV) developed by Sinovac Biotech Co., Ltd. (Sinovac, Beijing, China) by comparing its immunogenicity and safety with a comparator QIV (Vaxigrip Tetra^®) in a population aged 3 years an...

Повний опис

Бібліографічні деталі

Автори:	Wanqi Yang, Pablo A. González, Qianqian Xin, Mari Rose De Los Reyes, Ralph Elvi Villalobos, Charissa Fay Corazon Borja-Tabora, Nancy Nazaire Bermal, Alexis M. Kalergis, Dan Yu, Wenbin Wu, Susan M. Bueno, Liqun Huo, Mario Calvo, QINF Study Group, Gang Zeng, Jing Li
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2024-08-01
Серія:	Vaccines
Предмети:	quadrivalent influenza vaccine non-inferiority immunogenicity safety
Онлайн доступ:	https://www.mdpi.com/2076-393X/12/8/892
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!